Related Experiment Video
Updated: Jun 26, 2026
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Biophysical and Biochemical Assays for Screening Small Molecule Inhibitors Targeting Toxin-Ribosome Interactions.
Eric J Bryan1, Vishal Vijayanand2, Xiao-Ping Li1
1Department of Plant Biology, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, 59 Dudley Road, New Brunswick, NJ 08901, USA.
Developing inhibitors for ribosome-inactivating proteins requires targeting the toxin-ribosome interface. This review evaluates biophysical and biochemical assays crucial for discovering small molecules that disrupt these interactions and advance therapeutics.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Ribosome-inactivating proteins (RIPs) are potent toxins targeting eukaryotic ribosomes, inhibiting protein synthesis and causing cell death.
- Notable RIPs like ricin, Shiga toxin, and mucoricin pose significant public health threats, with no approved therapeutics currently available.
- Targeting the catalytic active site of RIPs has proven challenging due to its structural properties, necessitating alternative strategies.
Purpose of the Study:
- To review and evaluate biophysical and biochemical assays for discovering and characterizing small-molecule inhibitors of toxin-ribosome interactions.
- To explore strategies for identifying inhibitors that target the ribosome-binding interface of RIPs, offering a more druggable target.
- To highlight opportunities for refining assay methodologies to accelerate the development of targeted therapeutics against RIPs.
Main Methods:
- Evaluation of in vitro binding assays, including surface plasmon resonance (SPR) fragment screening and fluorescence anisotropy, for assessing inhibitor binding affinity.
- Review of biochemical and molecular assays measuring ribosome protection from toxin-induced depurination.
- Analysis of cell-based assays to evaluate the functional rescue of protein synthesis in cellular systems.
Main Results:
- The ribosome-binding interface presents a more tractable target for inhibitor development compared to the catalytic active site.
- Inhibitors targeting the binding interface can induce allosteric effects, disrupting catalytic activity indirectly.
- A range of assays, from in vitro binding to cell-based functional rescue, are available for inhibitor screening and validation.
Conclusions:
- Robust assay strategies are essential for identifying and validating small molecules that disrupt toxin-ribosome interactions.
- Targeting the ribosome-binding interface offers a promising avenue for developing novel therapeutics against dangerous RIPs.
- Refining current screening methodologies will support the advancement of effective treatments for RIP-mediated toxicity.
